Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

16.66 -0.02 (-0.12%)

Streaming Delayed Price Updated: 10:52 AM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Bausch Lomb BLCO Q2 2025 Earnings Transcript ↗

April 21, 2026

Bausch Lomb BLCO Q2 2025 Earnings Transcript

Via The Motley Fool

Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript ↗

April 21, 2026

Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript

Via The Motley Fool

Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript ↗

April 21, 2026

Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Initial Public Offering

Bausch + Lomb Corp (NYSE:BLCO) Reports Mixed Q4 2025 Results: Revenue Beat, EPS Miss ↗

February 18, 2026

Via Chartmill

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

April 16, 2026

From Bausch + Lomb Corporation

Via Business Wire

3 Cash-Burning Stocks We Keep Off Our Radar

April 10, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Via StockStory

Topics Bankruptcy

Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update

April 08, 2026

From Bausch + Lomb Corporation

Via Business Wire

1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off

April 08, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Via StockStory

Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe

April 07, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

April 06, 2026

From Bausch + Lomb Corporation

Via Business Wire

Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks

April 01, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and...

Via StockStory

Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29

March 30, 2026

From Bausch + Lomb Corporation

Via Business Wire

3 Reasons BLCO is Risky and 1 Stock to Buy Instead

March 26, 2026

Even during a down period for the markets, Bausch + Lomb has gone against the grain, climbing to $16.01. Its shares have yielded a 10.4% return over the last...

Via StockStory

Topics Bankruptcy

A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗

March 24, 2026

Bausch + Lomb, a global leader in eye health products and surgical devices, reported a recent insider buy amid ongoing sector activity.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma

March 23, 2026

From Bausch + Lomb Corporation

Via Business Wire

Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗

March 12, 2026

This outdoor advertising firm operates a vast network of displays across the Americas and Europe, serving a diverse global client base.

Via The Motley Fool

Topics Regulatory Compliance

Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position ↗

March 12, 2026

Bausch + Lomb provides eye health products and surgical devices globally, serving both healthcare professionals and consumers.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb Launches R&D “Teach-in” Webinar Series

March 09, 2026

From Bausch + Lomb Corporation

Via Business Wire

Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know

March 06, 2026

Via StockStory

Topics Earnings Economy

2 Profitable Stocks Worth Investigating and 1 We Ignore

March 04, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call

February 25, 2026

Bausch + Lomb’s fourth quarter showed strong revenue growth but fell short on non-GAAP profit expectations, prompting a modestly negative market reaction. Management attributed the performance to...

Via StockStory

Topics Earnings

Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

February 24, 2026

From Bausch + Lomb Corporation

Via Business Wire

3 Small-Cap Stocks We Steer Clear Of

February 22, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

BLCO Q4 2025 Deep Dive: Dry Eye and Product Innovation Propel Growth, Margin Expansion in Focus

February 19, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43...

Via StockStory

Bausch + Lomb’s (NYSE:BLCO) Q4 CY2025: Beats On Revenue

February 18, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q4 CY2025, with sales up 9.8% year on year to $1.41 billion. The company’s full-year revenue guidance of $5.43...

Via StockStory

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

February 18, 2026

From Bausch + Lomb Corporation

Via Business Wire

Bausch + Lomb (BLCO) Q4 Earnings: What To Expect

February 16, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting results this Wednesday before market hours. Here’s what to look for.

Via StockStory

Topics World Trade

3 Reasons to Sell BLCO and 1 Stock to Buy Instead

February 09, 2026

Bausch + Lomb’s 24.2% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $16.93 per share. This was partly thanks to its solid quarterly results, and...

Via StockStory

Topics Bankruptcy Stocks

1 Healthcare Stock to Research Further and 2 Facing Headwinds

January 29, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

Via StockStory

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.